32,788 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Verition Fund Management LLC

Verition Fund Management LLC bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,788 shares of the company's stock, valued at approximately $493,000. Verition Fund Management LLC owned 0.07% of Pacira BioSciences as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. FORA Capital LLC bought a new stake in shares of Pacira BioSciences in the 3rd quarter valued at approximately $431,000. BNP Paribas Financial Markets boosted its stake in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock valued at $5,955,000 after buying an additional 288,662 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Pacira BioSciences in the 3rd quarter valued at $257,000. Algert Global LLC bought a new stake in Pacira BioSciences in the third quarter valued at $886,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Pacira BioSciences by 4.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 431,897 shares of the company's stock worth $6,500,000 after acquiring an additional 16,819 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PCRX. Jefferies Financial Group boosted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Royal Bank of Canada boosted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "buy" rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. Finally, Barclays decreased their price target on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $23.50.

Pacira BioSciences Trading Down 2.6 %

Shares of Pacira BioSciences stock traded down $0.53 during trading on Thursday, reaching $19.80. 600,373 shares of the company were exchanged, compared to its average volume of 853,034. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $35.95. The business has a 50-day moving average price of $17.21 and a 200-day moving average price of $19.18. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $914.23 million, a price-to-earnings ratio of -9.75 and a beta of 0.80.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.